{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:30:41Z","timestamp":1761823841003},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T00:00:00Z","timestamp":1465862400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s00115-016-0138-5","type":"journal-article","created":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T12:20:32Z","timestamp":1465906832000},"page":"853-859","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Botulinumtoxin\u00a0A in der Kopfschmerztherapie","Botulinum toxin type A in headache treatment"],"prefix":"10.1007","volume":"87","author":[{"given":"C.","family":"Gaul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Holle-Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Straube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,14]]},"reference":[{"key":"138_CR1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1129-2377-15-58","volume":"15","author":"K Aaseth","year":"2014","unstructured":"Aaseth K, Grande RB, Lundqvist C et al (2014) Pericranial tenderness in chronic tension-type headache: the Akershus population-based study of chronic headache. J Headache Pain 15:58","journal-title":"J Headache Pain"},{"key":"138_CR2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1186\/s40064-015-1386-8","volume":"4","author":"F Ahmed","year":"2015","unstructured":"Ahmed F, Zafar HW, Buture A et\u00a0al (2015) Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse. Springerplus 4:589","journal-title":"Springerplus"},{"key":"138_CR3","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","volume":"30","author":"SK Aurora","year":"2010","unstructured":"Aurora SK, Dodick DW, Turkel CC et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793\u2013803","journal-title":"Cephalalgia"},{"key":"138_CR4","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","volume":"51","author":"SK Aurora","year":"2011","unstructured":"Aurora SK, Winner P, Freeman MC et al (2011) OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 51:1358\u20131373","journal-title":"Headache"},{"key":"138_CR5","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1046\/j.1468-2982.2000.00070.x","volume":"20","author":"L Bendtsen","year":"2000","unstructured":"Bendtsen L (2000) Central sensitization in tension-type headache\u2013possible pathophysiological mechanisms. Cephalalgia 20:486\u2013508","journal-title":"Cephalalgia"},{"key":"138_CR6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102411434808","volume":"32","author":"A Blaschek","year":"2012","unstructured":"Blaschek A, Milde-Busch A, Straube A et al (2012) Self reported muscle pain in adolescents with migraine and tension-type headache. Cephalalgia 32:241\u2013249","journal-title":"Cephalalgia"},{"key":"138_CR7","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.pain.2014.03.001","volume":"155","author":"N Boyer","year":"2014","unstructured":"Boyer N, Dallel R, Artola A et\u00a0al (2014) General trigeminospinal central sensitization and impaired descending pain inhibitory controls contribute to migraine progression. Pain 155:1196\u20132205","journal-title":"Pain"},{"key":"138_CR8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/0333102415597891","volume":"36","author":"DF Bratbak","year":"2015","unstructured":"Bratbak DF, Nordg\u00e5rd S, Stovner LJ et\u00a0al (2015) Pilot study of sphenopalatine injection of onabotulinumtoxin A for the treatment of intractable chronic cluster headache. Cephalalgia 36:503","journal-title":"Cephalalgia"},{"key":"138_CR9","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13063-015-1052-z","volume":"16","author":"J Burmeister","year":"2015","unstructured":"Burmeister J, Holle D, Bock E et\u00a0al (2015) Botulinum neurotoxin type A in the treatment of classical Trigeminal Neuralgia (BoTN): study protocol for a randomized controlled trial. Trials 16:550","journal-title":"Trials"},{"key":"138_CR10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/head.12372","volume":"54","author":"E Cernuda-Moroll\u00f3n","year":"2014","unstructured":"Cernuda-Moroll\u00f3n E, Mart\u00ednez-Camblor P, Ram\u00f3n C et al (2014) CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine. Headache 54:987\u2013995","journal-title":"Headache"},{"key":"138_CR11","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/j.pain.0000000000000119","volume":"156","author":"E Cernuda-Moroll\u00f3n","year":"2015","unstructured":"Cernuda-Moroll\u00f3n E, Ram\u00f3n C, Mart\u00ednez-Camblor P et al (2015) Onabotulinumtoxin A decreases interictal CGRP plasma levels in patients with chronic migraine. Pain 156:820\u2013824","journal-title":"Pain"},{"key":"138_CR12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1177\/0333102413485658","volume":"33","author":"Committee of the International Headache Society (IHS)","year":"2013","unstructured":"Committee of the International Headache Society (IHS) (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33:629\u2013808","journal-title":"Cephalalgia"},{"key":"138_CR13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2169\/internalmedicine.52.9161","volume":"52","author":"D Danno","year":"2013","unstructured":"Danno D, Kawabata K, Tachibana H (2013) Three cases of nummular headache effectively treated with Neurotropin(\u00ae). Intern Med 52:493\u2013495","journal-title":"Intern Med"},{"key":"138_CR14","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","volume":"30","author":"HC Diener","year":"2010","unstructured":"Diener HC, Dodick DW, Aurora SK et al (2010) Onabotulinumtoxin A for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804\u2013814","journal-title":"Cephalalgia"},{"key":"138_CR15","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/j.1526-4610.2008.01245.x","volume":"48","author":"P Dusitanond","year":"2008","unstructured":"Dusitanond P, Young W (2008) Botulinum toxin type A\u2019s efficacy in nummular headache. Headache 48:1379","journal-title":"Headache"},{"key":"138_CR16","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.pain.2010.07.029","volume":"151","author":"P Gazerani","year":"2010","unstructured":"Gazerani P, Au S, Dong X et\u00a0al (2010) Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis. Pain 151:606\u2013616","journal-title":"Pain"},{"key":"138_CR17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pain.2008.10.005","volume":"141","author":"P Gazerani","year":"2009","unstructured":"Gazerani P, Pedersen NS, Staahl C et al (2009) Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 141:60\u201369","journal-title":"Pain"},{"key":"138_CR18","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/0333102415607070","volume":"36","author":"C Gaul","year":"2015","unstructured":"Gaul C, Diener HC, Silver N et al (2015) Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): a randomised controlled study. Cephalalgia 36:534","journal-title":"Cephalalgia"},{"key":"138_CR19","doi-asserted-by":"crossref","unstructured":"Gaul C, Liesering-Latta E, Sch\u00e4fer B et al (2015) Integrated multidisciplinary care of headache disorders: a narrative review. Cephalalgia. pii: 0333102415617413. (Epub ahead of print)","DOI":"10.1177\/0333102415617413"},{"key":"138_CR20","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.pain.2006.05.001","volume":"125","author":"H G\u00f6bel","year":"2006","unstructured":"G\u00f6bel H, Heinze A, Reichel G et al (2006) Dysport myofascial pa in study group. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomised double-blind placebo-controlled multicentre study. Pain 125:82\u201388","journal-title":"Pain"},{"issue":"Suppl 1","key":"138_CR21","first-page":"1","volume":"24","author":"Headache Classification Subcommittee","year":"2004","unstructured":"Headache Classification Subcommittee (2004) The international classification of headache disorders, 2nd edition. Cephalalgia 24(Suppl 1):1\u2013160","journal-title":"Cephalalgia"},{"key":"138_CR22","unstructured":"http:\/\/www.fachinfo.de\/pdf\/020408 . Zugegriffen: 23. November 2015"},{"key":"138_CR23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1129-2377-14-72","volume":"14","author":"Y Hu","year":"2013","unstructured":"Hu Y, Guan X, Fan L et\u00a0al (2013) Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review. J\u00a0Headache Pain 14:72","journal-title":"J Headache Pain"},{"key":"138_CR24","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.2012.505","volume":"307","author":"JL Jackson","year":"2012","unstructured":"Jackson JL, Kuriyama A, Hayashino Y (2012) Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA 307:1736\u20131745","journal-title":"JAMA"},{"key":"138_CR25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1533-2500.2007.00150.x","volume":"7","author":"L Kapural","year":"2007","unstructured":"Kapural L, Stillman M, Kapural M et\u00a0al (2007) Botulinum toxin occipital nerve block for the treatment of severe occipital neuralgia: a case series. Pain Pract 7:337\u2013340","journal-title":"Pain Pract"},{"key":"138_CR26","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s001150050754","volume":"72","author":"S Kelm","year":"2001","unstructured":"Kelm S, Gerats G, Chalkiadaki A et\u00a0al (2001) Reduction of pain and muscle spasms by botulinum toxin A. Nervenarzt 72:302\u2013306","journal-title":"Nervenarzt"},{"key":"138_CR27","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1177\/0333102411398402","volume":"31","author":"M Linde","year":"2011","unstructured":"Linde M, Hagen K, Salvesen et al (2011) Onabotulinum toxin A treatment of cervicogenic headache: a randomised, double-blind, placebo-controlled crossover study. Cephalalgia 31:797\u2013807","journal-title":"Cephalalgia"},{"key":"138_CR28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1600-0404.2011.01544.x","volume":"191","author":"M Linde","year":"2011","unstructured":"Linde M, Hagen K, Stovner LJ (2011) Botulinum toxin treatment of secondary headaches and cranial neuralgias: a review of evidence. Acta Neurol Scand Suppl 191:50\u201355","journal-title":"Acta Neurol Scand Suppl"},{"key":"138_CR29","first-page":"18","volume":"111","author":"D Magis","year":"2011","unstructured":"Magis D, Schoenen J (2011) Occipital nerve stimulation for intractable chronic cluster headache: new hope for a dreadful disease? Acta Neurol Belg 111:18\u201321","journal-title":"Acta Neurol Belg"},{"key":"138_CR30","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1526-4610.2007.00960.x","volume":"48","author":"NT Mathew","year":"2008","unstructured":"Mathew NT, Kailasam J, Meadors L (2008) Botulinum toxin type A for the treatment of nummular headache: four case studies. Headache 48:442\u2013447","journal-title":"Headache"},{"key":"138_CR31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s10194-015-0502-z","volume":"16","author":"S Miller","year":"2015","unstructured":"Miller S, Correia F, Lagrata S et\u00a0al (2015) OnabotulinumtoxinA for hemicrania continua: open label experience in 9 patients. J\u00a0Headache Pain 16:19","journal-title":"J Headache Pain"},{"key":"138_CR32","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1177\/0333102413493193","volume":"33","author":"O Mueller","year":"2013","unstructured":"Mueller O, Diener HC, Dammann P et\u00a0al (2013) Occipital nerve stimulation for intractable chronic cluster headache or migraine: a critical analysis of direct treatment costs and complications. Cephalalgia 33:1283\u20131291","journal-title":"Cephalalgia"},{"key":"138_CR33","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.3390\/toxins7083127","volume":"7","author":"HM Oh","year":"2015","unstructured":"Oh HM, Chung ME (2015) Botulinum toxin for neuropathic pain: a review of the literature. Toxins (Basel) 7:3127\u20133154","journal-title":"Toxins (Basel)"},{"key":"138_CR34","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ana.21427","volume":"64","author":"D Ranoux","year":"2008","unstructured":"Ranoux D, Attal N, Morain F et\u00a0al (2008) Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 64:274\u2013283","journal-title":"Ann Neurol"},{"key":"138_CR35","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/0333102412473667","volume":"33","author":"J Schoenen","year":"2013","unstructured":"Schoenen J, Jensen RH, Lant\u00e9ri-Minet M et al (2013) Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: a randomized, sham-controlled study. Cephalalgia 33:816\u2013830","journal-title":"Cephalalgia"},{"key":"138_CR36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jns.2013.05.003","volume":"331","author":"SD Silberstein","year":"2013","unstructured":"Silberstein SD, Blumenfeld AM, Cady RK et al (2013) OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 331:48\u201356","journal-title":"J Neurol Sci"},{"key":"138_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007533","author":"A Soares","year":"2014","unstructured":"Soares A, Andriolo RB, Atallah AN et\u00a0al (2014) Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database Syst Rev. doi:10.1002\/14651858.CD007533","journal-title":"Cochrane Database Syst Rev"},{"key":"138_CR38","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s10194-007-0400-0","volume":"8","author":"P Sostak","year":"2007","unstructured":"Sostak P, Krause P, F\u00f6rderreuther S et al (2007) Botulinum toxin type-A therapy in cluster headache: an open study. J Headache Pain 8:236\u2013241","journal-title":"J Headache Pain"},{"key":"138_CR39","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1007\/s00115-012-3680-9","volume":"83","author":"A Straube","year":"2012","unstructured":"Straube A, Gaul C, F\u00f6rderreuther S et al (2012) Therapie und Versorgung bei chronischer Migr\u00e4ne. Expertenempfehlung der Deutschen Migr\u00e4ne- und Kopfschmerzgesellschaft\/Deutsche Gesellschaft f\u00fcr Neurologie sowie der \u00d6sterreichischen Kopfschmerzgesellschaft\/Schweizerischen Kopfwehgesellschaft. Nervenarzt 83:1600\u20131608","journal-title":"Nervenarzt"},{"key":"138_CR40","first-page":"719","volume-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"A Straube","year":"2012","unstructured":"Straube A, Gaul C, Sandor P et\u00a0al et\u00a0al (2012) Therapie des episodischen und chronischen Kopfschmerzes vom Spannungstyp und anderer t\u00e4glicher Kopfschmerzen. In: Diener HC, Weimar C, Berlit P (Hrsg) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. Thieme, Stuttgart, S\u00a0719\u2013730"},{"key":"138_CR41","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1111\/j.1526-4610.2008.01089.x","volume":"48","author":"M Taylor","year":"2008","unstructured":"Taylor M, Silva S, Cottrell C (2008) Botulinum toxin type-A (BOTOX) in the treatment of occipital neuralgia: a pilot study. Headache 48:1476\u20131481","journal-title":"Headache"},{"key":"138_CR42","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(86)92070-2","volume":"8501","author":"JK Tsui","year":"1986","unstructured":"Tsui JK, Eisen A, Stoessl AJ et al (1986) Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 8501:245\u2013247","journal-title":"Lancet"},{"key":"138_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008257","author":"Z Waseem","year":"2011","unstructured":"Waseem Z, Boulias C, Gordon A et al (2011) Botulinum toxin injections for low-back pain and sciatica. Cochrane Database Syst Rev. doi:10.1002\/14651858.CD008257","journal-title":"Cochrane Database Syst Rev"},{"key":"138_CR44","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/0333102412441721","volume":"32","author":"CJ Wu","year":"2012","unstructured":"Wu CJ, Lian YJ, Zheng YK et al (2012) Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia 32:443\u2013450","journal-title":"Cephalalgia"},{"key":"138_CR45","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/head.12495","volume":"55","author":"JA Yerry","year":"2015","unstructured":"Yerry JA, Kuehn D, Finkel AG (2015) Onabotulinum toxin a for the treatment of headache in service members with a history of mild traumatic brain injury: a cohort study. Headache 55:395\u2013406","journal-title":"Headache"},{"key":"138_CR46","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1177\/0333102412452045","volume":"32","author":"RJ Zabalza","year":"2012","unstructured":"Zabalza RJ (2012) Sustained response to botulinum toxin in SUNCT syndrome. Cephalalgia 32:869\u2013872","journal-title":"Cephalalgia"},{"issue":"pii","key":"138_CR47","first-page":"1207","volume":"6","author":"JM Zakrzewska","year":"2006","unstructured":"Zakrzewska JM, Linskey ME (2006) Trigeminal neuralgia. BMJ Clin Evid 6(pii):1207","journal-title":"BMJ Clin Evid"},{"key":"138_CR48","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1212\/01.wnl.0000217914.30994.bd","volume":"66","author":"P Zeeberg","year":"2006","unstructured":"Zeeberg P, Olesen J, Jensen R (2006) Probable medication-overuse headache: the effect of a 2\u2011month drug-free period. Neurology 66:1894\u20131898","journal-title":"Neurology"},{"key":"138_CR49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1129-2377-15-65","volume":"15","author":"H Zhang","year":"2014","unstructured":"Zhang H, Lian Y, Ma Y et al (2014) Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J Headache Pain 15:65","journal-title":"J Headache Pain"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-016-0138-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-016-0138-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-016-0138-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T16:36:37Z","timestamp":1718642197000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-016-0138-5"}},"subtitle":["Bew\u00e4hrte und experimentelle Indikationen","Established and experimental indications"],"short-title":[],"issued":{"date-parts":[[2016,6,14]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["138"],"URL":"https:\/\/doi.org\/10.1007\/s00115-016-0138-5","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,14]]}}}